-
Mashup Score: 4
Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 55
Immune checkpoint inhibitors improve the efficacy of first-line chemotherapy for patients with programmed death-ligand 1 (PD-L1)-positive unresectable locally advanced/metastatic triple-negative breast cancer (aTNBC), but randomised data in rapidly relapsing aTNBC are scarce.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 11Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations - 1 day(s) ago
Selpercatinib (LOXO-292) and pralsetinib (BLU-667) are highly potent RET-selective protein tyrosine kinase inhibitors (TKIs) for treating advanced RET-altered thyroid cancers and non-small-cell lung cancer (NSCLC). It is critical to analyze RET mutants resistant to these drugs and unravel the molecular basis to improve patient outcomes.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 17
SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in pre- and post-menopausal women with ER+, HER2− advanced breast cancer. Parts A and B aim to determine the safety and tolerability of camizestrant monotherapy and define doses for clinical evaluation. Patients and Methods Women aged 18 years or older with metastatic or recurrent ER+, HER2− breast cancer, refractory (or intolerant) to therapy were assigned 25 mg up to 450 mg once daily (QD; escalation) or 75, 150, or 300 mg QD (expansion).
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 8
Dr. Parker and colleagues report in the current issue of Annals of Oncology the updated results of the RADICALS-RT randomized trial evaluating the superiority of adjuvant radiotherapy (ART) versus early salvage radiotherapy (eSRT).1 Based on the similar biochemical control results reported after a median follow-up of 4.9 years, eSRT was deemed by many as the standard of care for predominately clinically intermediate-risk men post-radical prostatectomy (RP). 2
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 19
In MONARCH 2, the addition of abemaciclib to fulvestrant significantly improved both progression-free survival (PFS) and overall survival (OS) in patients with HR+, HER2- advanced breast cancer (ABC) with disease progression on prior endocrine therapy (ET). In MONARCH 3, the addition of abemaciclib to a nonsteroidal aromatase inhibitor (NSAI) as initial therapy for HR+, HER2- ABC significantly improved PFS. Here, we present the prespecified final OS results for MONARCH 3.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 12MITO END-3: Efficacy of Avelumab immunotherapy according to molecular profiling in first-line endometrial cancer therapy - 13 day(s) ago
Immunotherapy combined with chemotherapy significantly improves progression-free survival compared to first-line chemotherapy alone in advanced endometrial cancer, with a much larger effect size in microsatellite-instability high (MSI-H) cases. New biomarkers might help to select patients that may have benefit among those with a microsatellite-stable (MSS) tumor.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 29
Programmed cell death protein 1(PD-1) axis blockade has become the mainstay in the treatment of recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC). PD-L1 is the only approved biomarker for patient selection; however, response rate is limited even among high expressors. Our primary objective was to investigate the association of immune-cell-related biomarkers in the tumor and tumor microenvironment with PD-1 checkpoint inhibitors’ outcomes in patients with R/M HNSCC.
Source: www.annalsofoncology.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort of patients with cancer and coronavirus 2019 (COVID-19) reported to the COVID-19 and Cancer Consortium (CCC19) to identify prognostic clinical factors, including laboratory measurements and anticancer therapies.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet-
Association of Clinical Factors & Recent Anti-Cancer Therapy with COVID-19 Severity among Patients with Cancer: A Report from the COVID-19 and Cancer Consortium [3/18/21] @PGrivasMDPhD @arkhaki et al. @COVID19nCCC @Annals_Oncology https://t.co/WH5PPJySj6 #CCC19 #COVID19nCancer https://t.co/5tkdMEWUXx
-
-
Mashup Score: 55
Following the approval of the first antibody-drug conjugates (ADCs) in the early 2000s, development has increased dramatically, with 14 ADCs now approved and >100 in clinical development. In lung cancer, trastuzumab deruxtecan (T-DXd) is approved in human epidermal growth factor receptor 2 (HER2)-mutated, unresectable or metastatic non-small cell lung cancer, with ADCs targeting HER3 (patritumab deruxtecan), trophoblast cell-surface antigen 2 (datopotamab deruxtecan and sacituzumab govitecan [SG]) and mesenchymal-epithelial transition factor (telisotuzumab vedotin) in late-stage clinical development.
Source: www.annalsofoncology.orgCategories: General Medicine News, Hem/OncsTweet
RT @ElisaAgostinett: Simultaneous publication in @Annals_Oncology! @OncoAlert https://t.co/gypkEProj4